ADMA BIOLOGICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $3.61 per share for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2020-11-05
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $3.65, a 20.82% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2019-03-31 was $4.61, a 28.77% increase year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-03-31 was $3.58, a 60.31% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $9.02, a 9.33% increase year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $3.97, a 2.93% decline from fiscal 2018.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $4.09, a 47.02% decline from fiscal 2017.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2017 was $7.72, a 3.74% decline from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $8.02, a 12.45% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2020-09-30 | $3.61 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $3.51 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $3.65 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $3.97 10-K · filed 2020-03-13 | |||
| 2019-09-30 | $3.94 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $4.04 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $4.61 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $4.09 10-K · filed 2020-03-13 | |||
| 2018-09-30 | $4.05 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $4.24 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $3.58 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $7.72 10-K · filed 2019-03-13 | |||
| 2017-09-30 | $8.03 10-Q · filed 2017-11-03 | |||
| 2017-06-30 | $9.12 10-Q · filed 2017-08-11 | |||
| 2017-03-31 | $9.02 10-Q · filed 2017-05-12 | |||
| 2016-12-31 | $8.02 10-K · filed 2018-03-29 | |||
| 2016-09-30 | $8.02 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | $8.02 10-Q · filed 2016-08-12 | |||
| 2016-03-31 | $8.25 10-Q · filed 2016-05-13 | |||
| 2015-12-31 | $9.16 10-K · filed 2017-02-24 | |||
| 2015-09-30 | $9.16 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | $9.16 10-Q · filed 2015-08-11 | |||
| 2015-03-31 | $7.46 10-Q · filed 2015-05-12 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-23 | |||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-10 | |||
| 2013-12-31 | $7.56 10-K · filed 2015-03-09 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-03-28 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |